Is (ARPO) Outperforming Other Medical Stocks This Year?
If you're interested in Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), then you might want to consider its beta (a...
New Strong Buy Stocks For April 20th
Is (ARPO) Outperforming Other Medical Stocks This Year?
New Strong Buy Stocks For May 26th
Immunovant (IMVT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
In the latest trading session, Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.63, marking a +1.69% move from the previous day.
New Strong Buy Stocks For May 21st
CINCINNATI, March 12, 2020 -- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular.
Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.72 in the latest trading session, marking a +0.61% move from the prior day.
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. Approximately 10-15% of those infected with the highly contagious SARS-CoV2 virus, the cause of COVID-19, develop ARDS with a death rate in the 2-10% range. Preclinical models, large human observational studies, and human genetic studies from leading groups worldwide have independently arrived at the concept that a vascular endothelial receptor, Tie2, may play a pivotal role in the defense against microvascular breach in acute respiratory distress syndrome (ARDS) 1-4.
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
While it may not be enough for some shareholders, we think it is good to see the Aerpio Pharmaceuticals, Inc...
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for April 24th
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced a restructuring of their licensing deal with a wholly owned subsidiary of Gossamer Bio Inc., GB004, Inc. (“Gossamer Bio”) (GOSS), for its HIF-1 alpha stabilizer, GB004. The deal continues the collaboration between Gossamer Bio’s strong gastrointestinal (“GI”) development team and Aerpio’s management team.
Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and.
CINCINNATI, May 07, 2020 -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat.
Is (ARPO) Outperforming Other Medical Stocks This Year?